華仁藥業(300110.SZ)前三季度淨利潤預增94.09%-131.06%
格隆匯10月8日丨華仁藥業(300110.SZ)公佈,預計2021年前三季度歸屬於上市公司股東的淨利潤1.05億元-1.25億元,同比增長94.09%-131.06%。業績變動原因如下:
1、去年同期,由於疫情原因,公司藥品業務受到一定影響。本報吿期,隨着國內疫情得到有效控制,公司不斷完善銷售渠道,開拓增量市場,填補空白區域,加強市場準入,積極響應國家、省級、地市級三級集採政策,藥品銷售較去年同期有所增長。
2、報吿期內,公司積極推動醫藥健康全產業鏈佈局,拓展醫藥商業業務,醫藥商業板塊穩步增長,貢獻了部分利潤。
3、2020年11月,公司收購廣西裕源藥業、浦北新科100%股權,並於2020年11月納入合併報表,報吿期內貢獻了部分利潤。
4、2021年8月,公司通過全資子公司曲江華仁收購西安恆聚星醫藥100%股權,並間接持有安徽恆星製藥100%股權,並於2021年8月納入合併報表,報吿期內貢獻了部分利潤。
報吿期內公司歸屬上市公司股東的非經常性損益約500萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.